Kymera Therapeutics Inc (KYMR)
34.94
-0.66
(-1.85%)
USD |
NASDAQ |
May 17, 16:00
34.94
0.00 (0.00%)
After-Hours: 20:00
Kymera Therapeutics Cash from Financing (TTM): 356.79M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 356.79M |
| December 31, 2023 | 4.192M |
| September 30, 2023 | 4.211M |
| June 30, 2023 | 154.91M |
| March 31, 2023 | 153.97M |
| December 31, 2022 | 153.00M |
| September 30, 2022 | 153.10M |
| Date | Value |
|---|---|
| June 30, 2022 | 248.64M |
| March 31, 2022 | 249.87M |
| December 31, 2021 | 250.28M |
| September 30, 2021 | 248.50M |
| June 30, 2021 | 198.73M |
| March 31, 2021 | 196.74M |
| December 31, 2020 | 289.26M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
4.192M
Minimum
Dec 2023
356.79M
Maximum
Mar 2024
190.16M
Average
197.73M
Median
Cash from Financing (TTM) Benchmarks
| Immunic Inc | 75.45M |
| Insmed Inc | 171.86M |
| SELLAS Life Sciences Group Inc | 30.06M |
| Iovance Biotherapeutics Inc | 398.36M |
| Intellia Therapeutics Inc | 188.09M |